Activating epidermal growth factor receptor (EGFR) mutations are observed in approximately 10–15% of Caucasian patients and 30–35% of Asian patients with non-small cell lung cancer (NSCLC) [1]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.